



CS/NSE&BSE/UFR/2018-19
August 14, 2018

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Stock Code: SUVEN–EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter ended 30th June, 2018

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 14th August, 2018, has taken on record the Un-audited Financial Results of the Company under Ind AS for the quarter ended 30th June, 2018.

We are enclosing herewith the following documents:

- a) Un-audited Financial Results under Ind AS for the quarter ended 30th June, 2018
- b) Limited Review Report of Statutory Auditors of the Company

We hereby notify that in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 our Company will submit standalone financial results for the financial year 2018-2019.

Please find enclosed **Press Release** of our company. We request you to take these documents on your records. The Board Meeting commenced at 3:00 P.M. and concluded at 4:45 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read "K Hanumantha Rao".

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th JUNE ' 2018

PART - I

Rs. In Lakhs

Sl. No.	PARTICULARS	For the Quarter Ended			For the year Ended
		30/06/2018	31/03/2018	30/06/2017	31/03/2018
		Un Audited	Audited	Un-Audited	Audited
1	Revenue from operations				
	(a) Net sales/income from operations	18,487.99	20,829.49	13,744.90	61,258.22
	(b) Other operating income	678.23	542.84	357.00	1,267.62
	Total income from operations (net)	19,166.22	21,372.33	14,101.90	62,525.84
2	Other Income	812.77	922.60	562.29	2,327.07
	Total income (1+2)	19,978.99	22,294.93	14,664.19	64,852.91
3	Expenses				
	a) Cost of materials consumed	3,859.30	4,483.78	3,683.53	17,490.30
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,595.82	1,482.12	(227.17)	(2,120.13)
	d) Employee benefits expense	1,714.82	1,557.92	1,566.22	5,873.50
	e) Finance costs	106.79	125.36	127.01	461.11
	f) Depreciation and amortisation expense	550.81	536.14	519.20	2,130.99
	g) Manufacturing Exps	2,285.50	2,150.75	2,190.37	8,821.54
	h) R & D Exps	1,598.87	1,691.51	1,601.19	5,846.66
	i) Other Expenses	1,288.81	882.03	759.06	3,322.37
	Total expenses	14,000.72	12,909.61	10,219.41	41,826.34
4	Profit / (Loss) before exceptional items & Tax (1+2-3)	5,978.27	9,385.32	4,444.78	23,026.57
5	Exceptional Items	-	-	-	-
6	Profit / (Loss) before Tax (4-5)	5,978.27	9,385.32	4,444.78	23,026.57
7	Tax Expenses				
	a) Current tax	1,249.14	2,016.93	1,132.77	4,756.49
	b) Deferred tax	844.92	1,117.28	354.94	2,427.35
8	Net Profit/ (Loss) for the period/year(6-7)	3,884.21	6,251.11	2,957.07	15,842.73
9	Other Comprehensive Income				
9.a	(i) Items that will not be reclassified to profit or loss	(10.58)	(31.15)	(3.73)	(42.33)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.66	10.78	1.29	14.65
9.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other Comprehensive Income	(6.92)	(20.37)	(2.44)	(27.68)
10	Total Comprehensive Income for the period (8+9)	3,877.29	6,230.74	2,954.63	15,815.05
11	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
12	Other Equity				85,397.16
13	Earning Per Share (EPS) (Face value of Rs.1/- each) :				
	a) Basic	3.05	4.90	2.32	12.43
	b) Diluted	3.05	4.90	2.32	12.43
		(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES

Rs in Lakhs

PARTICULARS	For the Quarter Ended			For the year Ended
	30/06/2018	31/03/2018	30/06/2017	31/03/2018
	Un Audited	Audited	Un-Audited	Audited
1 SEGMENT REVENUE :-				
a) Manufacturing (CRAMS)	18,024.22	20,636.53	13,330.76	59,687.64
b) Services (DDDSS)	1,142.00	735.80	771.14	2,838.20
c) Research & Development	-	-	-	-
TOTAL	19,166.22	21,372.33	14,101.90	62,525.84
Less Inter segment Revenue	-	-	-	-
Net Sales from Operations	19,166.22	21,372.33	14,101.90	62,525.84
2 SEGMENT RESULTS :-				
Profit/(Loss) before tax and interest:				
a) Manufacturing (CRAMS)	7,086.74	10,492.63	5,782.86	28,031.87
b) Services (DDDSS)	761.15	436.40	405.25	1,428.77
c) Research & Development	(1,598.88)	(1,691.51)	(1,601.18)	(5,846.66)
TOTAL	6,249.01	9,237.52	4,586.93	23,613.98
Less: i) Finance costs	35.97	47.88	87.11	281.59
ii) Other Un-allocable expenditure/(Income), net	234.77	(195.65)	55.04	305.82
Total Profit Before Tax	5,978.27	9,385.29	4,444.78	23,026.57
3 SEGMENT ASSETS :				
a) Manufacturing (CRAMS)	48,587.81	52,557.03	47,190.09	52,557.03
b) Services (DDDSS)	4,339.17	4,061.14	3,511.49	4,061.14
c) Research & Development	2,784.33	3,031.96	2,540.08	3,031.96
d) Un allocated	50,187.02	41,234.30	37,517.52	41,234.30
TOTAL	105,898.33	100,884.43	90,759.18	100,884.43
SEGMENT LIABILITIES :				
a) Manufacturing (CRAMS)	9,053.42	8,594.07	8,830.42	8,594.07
b) Services (DDDSS)	315.25	382.64	428.06	382.64
c) Research & Development	1,323.46	1,587.28	1,873.25	1,587.28
d) Un allocated	867.09	714.79	722.22	714.79
TOTAL	11,559.22	11,278.78	11,853.95	11,278.78

Notes:

- 1) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the period presented been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- 2) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th Aug 2018 and the same reviewed by the Statutory Auditors.
- 3) Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending June 2017. Post implementation of GST Act wef 1st July 2017 the revenue from operations is reported for the period ended June 2018 is net of GST and hence to that extent not comparable.
- 4) Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.
- 5) The figures for Qtr ended 31 Mar 2018 are the balancing figures between audited figures in respect of the full financial year ended 31 March 2018 and the published year to date reviewed figures upto the end of the 3rd Qtr ended 31 Dec 2017.
- 6) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD



Venkat Jasti

VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date : 14 th Aug ' 2018



Ref No.LR/SUVEN-Q1/2018-19:

LIMITED REVIEW REPORT

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying statement of Unaudited Financial Results ("The Statement") of **SUVEN LIFE SCIENCES LIMITED**, ("the Company") having registered office at SDE Serene Chambers, 6th Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the quarter ended on June 30, 2018, attached here with, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations,2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05, July 2016.

2. The Preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, Interim Financial reporting (IND AS 34) prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated 05 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to express conclusion on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Ind AS prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO.**,
Chartered Accountants
(Firm Registration No.004436S)

(RAJENDER REDDY K)
P A R T N E R
Membership No.231834



Place: Hyderabad
Date: August 14, 2018

News Release

Suven's Income at Rs. 1998 Mn; PAT at Rs. 388 Mn for the quarter ended June 2018

HYDERABAD, INDIA (14 August, 2018) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Aug 2018 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2018: (QoQ)

Growth in revenue	INR 1998 Mn vs. INR 2229 Mn - Down by 10.39%
Growth in PAT	INR 388 Mn vs. INR 623 Mn - Down by 37.77%
Growth in EBIDTA	INR 664 Mn vs. INR 1005 Mn - Down by 33.95%

Financial Highlights (comparison with same quarter, previous year):

Growth in revenue	INR 1998 Mn vs. INR 1466 Mn - Up by 36.24%
Growth in PAT	INR 388 Mn vs. INR 295 Mn - Up by 31.23%
Growth in EBIDTA	INR 664 Mn vs. INR 509 Mn - Up by 30.35%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 160 Mn (8% on revenue) for the quarter ended 30th June 2018.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor, Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com